Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial

Inclusion Criteria

• •Subjects need to fulfill all of the following 4 criteria:
• •1. Evidence of portal hypertension (by hemodynamic measurement, or by Doppler flow of portal circulation, or by clinical evidence of portal hypertension such as esophageal or gastric varices, as evidenced by prior upper endoscopy).
• •2. Evidence of pulmonary arterial hypertension by right heart catheterization (all three criteria need to be present) Right heart catheterization may have been performed up to 30 days prior to screening
• •* Mean PAP (pulmonary artery pressure) \>25 mm Hg, and
• •* PVR (pulmonary vascular resistance) \>240 dynes/s/cm5, and
• •* TPG (transpulmonary gradient = meanPAP -PAWP) \>12 mm Hg
• •3. Baseline AST, ALT \< 5 times the upper limit of normal, total Bili \< 3.0 mg/dl, and mild liver impairment with Child -Pugh class A or B
• •4. Ages 18 years and above